{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:20:25Z","timestamp":1787815225065,"version":"build-2784847793"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-026-09969-w","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:04:09Z","timestamp":1787814249000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interim analysis in clinical trials: caution against premature conclusions\u2014the SWOG multiple myeloma S0777 case study"],"prefix":"10.1186","volume":"27","author":[{"given":"Emily","family":"Goren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Hoering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"issue":"1","key":"9969_CR1","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2023.552","volume":"7","author":"JD Ciolino","year":"2023","unstructured":"Ciolino JD, Kaizer AM, Bonner LB. Guidance on interim analysis methods in clinical trials. J Clin Transl Sci. 2023;7(1): e124.","journal-title":"J Clin Transl Sci"},{"key":"9969_CR2","first-page":"247","volume-title":"Handbook of statistics in clinical oncology","author":"JJ Dignam","year":"2005","unstructured":"Dignam JJ, Bryant J, Wieand HS. Early stopping of cancer clinical trials. In: Handbook of statistics in clinical oncology. Chapman and Hall\/CRC; 2005. p. 247\u201366."},{"key":"9969_CR3","doi-asserted-by":"publisher","DOI":"10.2307\/2530245","author":"PC O'Brien","year":"1979","unstructured":"O\u2019Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979. https:\/\/doi.org\/10.2307\/2530245.","journal-title":"Biometrics"},{"key":"9969_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1002\/sim.4780131308","volume":"13","author":"DL Demets","year":"1994","unstructured":"Demets DL, Lan KKG. Interim analysis: the alpha spending function approach. Stat Med. 1994;13:1341\u201352.","journal-title":"Stat Med"},{"issue":"3","key":"9969_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/1740774511401636","volume":"8","author":"JR Anderson","year":"2011","unstructured":"Anderson JR, High R. Alternatives to the standard Fleming, Harrington, and O\u2019Brien futility boundary. Clin Trials. 2011;8(3):270\u20136.","journal-title":"Clin Trials"},{"issue":"1","key":"9969_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1740774516666502","volume":"14","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Freidlin B, Korn EL, Halabi S, Mandrekar S, Dignam JJ. Comparison of futility monitoring guidelines using completed phase III oncology trials. Clin Trials. 2017;14(1):48\u201358.","journal-title":"Clin Trials"},{"issue":"10","key":"9969_CR7","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1200\/JCO.2008.19.5339","volume":"27","author":"EL Korn","year":"1990","unstructured":"Korn EL, Freidlin B, Mooney M. Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute cooperative group experience from 1990 to 2005. J Clin Oncol. 1990;27(10):1712\u201321.","journal-title":"J Clin Oncol"},{"issue":"4","key":"9969_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S0197-2456(02)00218-0","volume":"23","author":"B Freidlin","year":"2002","unstructured":"Freidlin B, Korn EL. A comment on futility monitoring. Control Clin Trials. 2002;23(4):355\u201366.","journal-title":"Control Clin Trials"},{"issue":"7","key":"9969_CR9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/annonc\/mdx042","volume":"28","author":"E Lesaffre","year":"2017","unstructured":"Lesaffre E, Edelman MJ, Hanna NH, Park K, Thatcher N, Willemsen S, et al. Statistical controversies in clinical research: futility analyses in oncology\u2013lessons on potential pitfalls from a randomized controlled trial. Ann Oncol. 2017;28(7):1419\u201326.","journal-title":"Ann Oncol"},{"key":"9969_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDctw2100020","author":"SS Ellenberg","year":"2022","unstructured":"Ellenberg SS, Shaw PA. Early termination of clinical trials for futility \u2014 considerations for a data and safety monitoring board. NEJM Evid. 2022. https:\/\/doi.org\/10.1056\/EVIDctw2100020.","journal-title":"NEJM Evid"},{"issue":"4","key":"9969_CR11","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/pst.216","volume":"5","author":"S Snapinn","year":"2006","unstructured":"Snapinn S, Chen MG, Jiang Q, Koutsoukos T. Assessment of futility in clinical trials. Pharm Stat. 2006;5(4):273\u201381.","journal-title":"Pharm Stat"},{"issue":"10068","key":"9969_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BG Durie","year":"2017","unstructured":"Durie BG, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327.","journal-title":"Lancet"},{"issue":"14","key":"9969_CR13","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1200\/JCO.18.02096","volume":"37","author":"J Mikhael","year":"2019","unstructured":"Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, et al. Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline. J Clin Oncol. 2019;37(14):1228\u201363.","journal-title":"J Clin Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09969-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09969-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09969-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:04:10Z","timestamp":1787814250000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09969-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9969"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09969-w","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The SWOG S0777 study was conducted in accordance with the Declaration of Helsinki and other relevant\u00a0guidelines and regulations. The protocol received institutional review board approval from eachguidelines and regulations. The protocol received institutional review board approval from each\u00a0participating center. All patients studied provided written informed consent for participation in a SWOG\u00a0clinical trial.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have seen and approved the final version and agree to its submission for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"550"}}